Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.56 |
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729989 | 0.88 | PTGER1 (0.64) | PTGER1PARP1PARP2MRGPRX4CNR1 | |
| SCHEMBL3926335 | 0.88 | PTGER1 (0.67) | PTGER1NPC1RAB9AMRGPRX4MCL1 | |
| SCHEMBL1315450 | 0.87 | PTGER1 (0.59) | PTGER1NPC1RAB9AMRGPRX4MCL1 | |
| SCHEMBL31375951 | 0.87 | PTGER1 (0.58) | PTGER1NPC1RAB9AMRGPRX4MCL1 | |
| SCHEMBL21447041 | 0.86 | NPC1 (0.58) | PTGER1NPC1RAB9AMRGPRX4KMT2A | |
| SCHEMBL11357851 | 0.85 | MAOB (0.61) | PTGER1MRGPRX4MCL1 | |
| SCHEMBL3454792 | 0.85 | PARP15 (0.62) | PARP1PARP10KMT2A | |
| SCHEMBL11355488 | 0.83 | PTGER1 (0.54) | PTGER1NPC1RAB9AMRGPRX4MCL1 | |
| SCHEMBL21434703 | 0.83 | PTGER1 (0.57) | PTGER1NPC1RAB9AMRGPRX4MCL1 | |
| SCHEMBL5110061 | 0.81 | PTGER1 (0.81) | PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492414-B2 | Antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-07-23 | — | — | US | disclosed |
| US-8492414-B2 | Antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-07-23 | — | — | US | disclosed |
| EP-2200991-B1 | ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20100273837-A1 | ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273837-A1 | ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-2200991-A1 | ANTIBACTERIAL AGENTS | Biota Europe Ltd (GB) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009037485-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273837-A1 | ANTIBACTERIAL AGENTS | SQOR, SCO2, CYCS | PTGER1 3019/4885PARP1 1632/4885PARP2 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.